Abstract
BackgroundConcerns of intraocular inflammation associated with intravitreal administration of anti-VEGF drugs have been risen and the exact mechanism is not yet elucidated. ObjectiveTo explore the relationship between immunogenicity and intraocular inflammation in intravitreal anti-VEGF drugs. MethodsThis review examines the immunogenicity of individual intravitreal anti-VEGF drugs and their potential link to intraocular inflammation. ResultsWe suggest that the main cause of intraocular inflammation is the presence of pre-existing and treatment-induced antidrug antibodies, along with considerations related to the molecular structure, which includes the drug's format and size. ConclusionsResearchers and clinicians involved in the advancement of new anti-VEGF drugs should take into consideration the factors related to intraocular inflammation that have been discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
